Chronic Hepatitis C
Conditions
Keywords
HCV
Brief summary
This project is a randomized trial of two strategies to treat persons with genotype 1 HCV who currently inject drugs (PWIDs) with a once daily regime of ledipasvir-sofosbuvir (LDV-SOF) for 8 weeks. The study will enroll 30 participants and will assess the feasibility and acceptability of treating active PWIDs for HCV with LDV-SOF by modified directly observed therapy (mDOT) versus unobserved dosing, with motivational interviewing based adherence support; and assess through in-depth, semi-structured qualitative interviews, the challenges with time intensity required for mDOT and unobserved dosing interventions, and identify key factors affecting treatment adherence.
Interventions
OTHERunobserved dosing
Motivational Interviewing-based risk reduction and medication adherence counseling
Sponsors
National Institute on Drug Abuse (NIDA)
Phillip Coffin, MD, MIA
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. ≥18 years of age; 2. 2 consecutive positive HCV RNA tests at least 6 months after estimated date of infection; 3. HCV genotype 1; 4. HCV RNA \<6 million copies by Roche TaqMan Assay 5. No evidence of hepatic cirrhosis (as determined by two indices: Fib4\<3.25-an accurate test for detecting cirrhosis based on age, AST, ALT and platelets \[sensitivity/specificity 76-100/82-91%\], confirmed by the fibrosis-cirrhosis index (FCI)\<1.25 based on ALT, bilirubin, albumin and platelets \[sensitivity/specificity 86/100%\]); 6. Drug injection in past 30 days by self-report and physical exam evidence of injection drug use (e.g. track marks), 7. injected with others in past 12 months by self-report; 8. Lab values within acceptable range (platelets\>50,000, creatinine clearance by Cockroft-Gault\>30mL/min, hemoglobin \>10g/dL, INR\<1.5 x upper limit of normal (ULN) unless stable on anticoagulant regimen or known hemophilia, AST/ALT\<10 x ULN); 9. Able to speak English; 10. No plans to leave San Francisco area for at least 9 months and either lives or works in San Francisco, or travels to San Francisco at least weekly; 11. for women of childbearing age, pregnancy test negative, not actively nursing, and agree to use birth control during treatment (although LDV-SOF has a B rating, consistent with no known evidence of harm, treatment is not urgent for these patients so we will err on the side of caution).
Exclusion criteria
1. HIV+ by rapid test or pooled viral load; 2. HBV surface antigen +; 3. Non-definitive HCV genotype results; 4. Previously received treatment for HCV (interferon, ribavirin, or DAA); 5. Taking medications that affect pharmacokinetics of LDV-SOF (proton-pump inhibitors, anticonvulsants \[phenobarbital, phenytoin, carbamazepine, oxcarbazepine\], rifamycins, rosuvastatin, herbs \[St. John's wort, silymarin, echinacea\]); 6. History of any of the following: 1. Current gastrointestinal disorder or post-operative condition that could interfere with the absorption of the study drug 2. History of hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage) 3. History of solid organ or bone marrow transplantation. 4. Current treatment for cancer 7. Chronic liver disease for non HCV reason, except iron overload (e.g., Wilson's disease, alfa 1 antitrypsin deficiency, cholangitis); 8. Use of any prohibited concomitant medications as described in Section 5.2 within 21 days of the Day 1 visit; and 9. Known hypersensitivity to LDV, SOF, the metabolites, or formulation excipients. 10. No other conditions that preclude study involvement as determined by PI.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of people who inject drugs (PWIDs) with HCV who were recruited and retained | 44 weeks | To determine the feasibility of treating active PWIDs for HCV with LDV-SOF by mDOT versus unobserved dosing based on proportion eligible and enrolled among those screened and completion rates overall and by arm. |
| Medication adherence to study drug | 44 weeks | To evaluate the acceptability of mDOT versus unobserved dosing, the percent of treatment medication adherence to LDV-SOF, as measured by the percent of doses taken overall (observed and unobserved), will be assessed using DOT doses and weekend Wise Pill data for the mDOT arm, and WisePill data for the unobserved dosing arm. |
| Challenges of medication adherence | 44 weeks | To assess through in-depth, semi-structured qualitative interviews, the challenges with time intensity required for mDOT versus unobserved dosing for PWIDs treated with LDV-SOF. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SVR (end-of-treatment response) | 12 weeks | We will compare the proportion of participants with undetectable HCV RNA at week 8 and post-treatment week 12 between arms. |
| Social and injector networks of participants | 44 weeks | We will characterize injector network sizes at baseline and follow-up through ACASI surveys. |
| SOF/metabolite levels | 8 weeks | SOF/metabolite-positivity rates will be calculated by week in both arms. |
| HCV relapse and reinfection | 36 weeks | Among participants who achieve SVR, we will determine the proportion who experience HCV relapse and reinfection at post-treatment week 36, overall and by arm. |
Countries
United States
Outcome results
None listed